Senators Ask Gilead to Explain Cost of Sovaldi Hepatitis DrugSenators Ask Gilead to Explain Cost of Sovaldi Hepatitis Drug

Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough new treatment for hepatitis C. Reuters Health Information
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Infectious Diseases News Source Type: news